Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19-Reference-Cited by-同舟云学术

Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19

Published:2021-03-24 Issue:3 Volume:4 Page:e213071
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Garibaldi Brian T.¹,Wang Kunbo²,Robinson Matthew L.³,Zeger Scott L.⁴,Bandeen-Roche Karen⁴,Wang Mei-Cheng⁴,Alexander G. Caleb⁵,Gupta Amita³,Bollinger Robert³,Xu Yanxun²⁶

Affiliation:

1. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

2. Department of Applied Mathematics and Statistics, Johns Hopkins University, Baltimore, Maryland

3. Division of Infectious Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland

4. Division of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

5. Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

6. Division of Biostatistics and Bioinformatics at The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2777863/garibaldi_2021_oi_210112_1616042465.1957.pdf

Reference34 articles.

1. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir.;Tchesnokov;Viruses,2019

2. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19.;Jorgensen;Pharmacotherapy,2020

3. A randomized, controlled trial of Ebola virus disease therapeutics.;Mulangu;N Engl J Med,2019

4. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.;Wang;Cell Res,2020

5. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.;Williamson;Nature,2020

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 viral load is linked to remdesivir efficacy in severe Covid-19 admitted to intensive care;Scientific Reports;2024-09-06

2. The treatment of COVID-19: lessons learned and future directions;Future Virology;2024-08-12

3. Persistence of SARS‐CoV‐2 infection and viral intra‐ and inter‐host evolution in COVID‐19 hospitalized patients;Journal of Medical Virology;2024-05-28

4. Real-world evidence of survival benefit of remdesivir: study of 419 propensity score-matched patients hospitalized over the alpha and delta waves of COVID-19 in New Orleans, LA;Frontiers in Medicine;2024-05-16

5. Efficacy of Remdesivir on Clinical Outcomes in COVID-19 Patients: A Study in a Tertiary Care Hospital in Pakistan;Journal of Community Hospital Internal Medicine Perspectives;2024-05-07